AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Guyana’s AI Push Shows How Smaller Health Systems Are Leapfrogging With Digital Infrastructure
Guyana is integrating AI to modernize public healthcare, adding to a growing list of countries using digital tools to compensate for infrastructure gaps. The story shows how smaller systems may be more willing to embrace AI not as an add-on, but as a core modernization strategy.
Kenya’s AI Partnerships Point to a Faster Digital Health Future
Kenya is accelerating its digital health strategy through AI partnerships, reinforcing its position as one of Africa’s more active health-tech markets. The story suggests that cross-border collaboration is becoming a practical route to expanding access and modernization.
BioPharma Dive: Lilly’s AI Expansion Shows Big Pharma Is Building a Portfolio, Not Picking a Winner
BioPharma Dive’s coverage of Lilly’s expanded work with Insilico points to a broader strategic pattern: large pharmaceutical companies are constructing diversified AI discovery portfolios rather than betting on a single platform. That approach mirrors how pharma manages scientific risk in every other part of R&D.
GEN: Lilly’s Expanded AI Footprint Shows Big Pharma Is Building Discovery Capacity Through Portfolios, Not Bets
Genetic Engineering & Biotechnology News frames Lilly’s latest collaboration as part of a broader expansion of its AI footprint. The significance is strategic: large pharma increasingly appears to be treating AI partnerships as a portfolio-building exercise across modalities and programs, rather than as isolated moonshots.
Fierce Biotech sees Lilly’s expanded Insilico pact as a signal of deeper pharma-AI integration
Fierce Biotech’s coverage of Lilly’s latest Insilico agreement emphasizes that the relationship is expanding rather than remaining a one-off experiment. That persistence is meaningful in a market where many AI-biopharma tie-ups have generated attention but limited visible strategic follow-through.
Purple Biotech’s AI Antibody Deal Highlights a More Focused Commercial Model for Biotech AI
Purple Biotech has entered an AI-powered tri-specific antibody deal, adding to evidence that partnerships are shifting from broad platform narratives toward targeted modality-specific collaborations. The move shows how AI is becoming embedded in narrower, commercially legible programs where value can be tied to a specific therapeutic format and development milestone path.
Insilico and ASKA Take AI Drug Discovery Into Gynecological Disease
Insilico Medicine and ASKA have partnered to apply AI-driven discovery tools to gynecological diseases, a therapeutic area that has often received less platform attention than oncology or immunology. The deal is notable because it tests whether AI-led discovery can create value in more specialized, under-addressed disease domains where data may be thinner and biology more heterogeneous.
PharmaMar and Globant Bring AI to Oncology Research, Underscoring the Build-vs-Partner Reality
PharmaMar’s collaboration with Globant to accelerate oncology research illustrates how mid-sized and specialist biopharma companies are turning to external partners to operationalize AI. The deal reflects a broader market dynamic: not every company will build proprietary AI stacks, but many still want targeted advantage in discovery and translational work.
Bristol Myers Squibb and Microsoft Bring AI Into the Front End of Lung Cancer Detection
Bristol Myers Squibb and Microsoft are partnering to improve early lung cancer detection using AI, signaling continued pharmaceutical interest in diagnostics-adjacent infrastructure. The move reflects a broader industry strategy: influencing patient identification and care pathways earlier, not just competing at the treatment stage.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.